Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pine-labs-pvt-ltd" target="_blank" data-smartkarma-citation="entities:33472:1" rel="noopener">Pine Labs</a> is looking to raise up to US$1bn in its upcoming India IPO.</li>
<li>Pine Labs (PL) is a fintech firm focused on digitizing commerce through digital payments and issuing solutions for merchants, consumer brands and enterprises, and financial institutions.</li>
<li>In this note, we talk about the positive aspects of the deal.</li>
</ul>



Pine Labs is looking to raise up to US$1bn in its upcoming India IPO.
Pine Labs (PL) is a fintech firm focused on digitizing commerce through digital payments and issuing solutions for merchants, consumer brands and enterprises, and financial institutions.
In this note, we talk about the positive aspects of the deal.


Pine Labs Pre-IPO - The Positives - Some Segments Growing..

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

Anthem Biosciences / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener">Anthem Biosciences (1234D IN)</a> is looking to raise about US$397m in its India IPO.</li>
<li>Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.</li>
<li>We have looked at the company’s past performance in our previous notes. In this note, we will talk about the RHP updates.</li>
</ul>



Anthem Biosciences (1234D IN) is looking to raise about US$397m in its India IPO.
Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.
We have looked at the company’s past performance in our previous notes. In this note, we will talk about the RHP updates.


Anthem Biosciences IPO - D&M Vertical Continues to Drive CRDMO Business

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/swiggy-limited" target="_blank" data-smartkarma-citation="entities:35630:1" rel="noopener">Swiggy (SWIGGY IN)</a> listed in November 2024 and around 85% of the shares outstanding (US$7.6bn) will unlock on 13 May.</li>
<li>Nearly 80% of the shares that unlock are held by pre-IPO PE/VC investors and they are 100% in the money in most cases. Expect the selldown to commence soon.</li>
<li>
<a href="https://www.smartkarma.com/entities/swiggy-limited" target="_blank" data-smartkarma-citation="entities:35630:1" rel="noopener">Swiggy (SWIGGY IN)</a> should be added to one global index in June, while inclusion in the other global index will require a small price increase or selling from PE/VC investors.</li>
</ul>



Swiggy (SWIGGY IN) listed in November 2024 and around 85% of the shares outstanding (US$7.6bn) will unlock on 13 May.
Nearly 80% of the shares that unlock are held by pre-IPO PE/VC investors and they are 100% in the money in most cases. Expect the selldown to commence soon.

Swiggy (SWIGGY IN) should be added to one global index in June, while inclusion in the other global index will require a small price increase or selling from PE/VC investors.


Swiggy (SWIGGY IN): US$7.6bn Lock-Up Expiry & Index Inclusion

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>The cabinet approved a Rs. 22,919 cr PLI for non-semiconductor electronics to boost domestic manufacturing, aiming for significant investment and job creation.</li>
<li>
<a href="https://www.smartkarma.com/entities/national-stock-exchange" target="_blank" data-smartkarma-citation="entities:23751:1" rel="noopener">National Stock Exchange (NSEIN IN)</a>'s IPO, initially filed in 2016, faces a potential two-year delay due to regulatory concerns flagged by SEBI, despite recent improvements in share transfer efficiency.</li>
<li>India's defence manufacturing achieved Rs. 1.27 lakh crore output in FY24 and aims for Rs. 3 lakh crore by 2029 through indigenous development and policy reforms.</li>
</ul>


The cabinet approved a Rs. 22,919 cr PLI for non-semiconductor electronics to boost domestic manufacturing, aiming for significant investment and job creation.

National Stock Exchange (NSEIN IN)'s IPO, initially filed in 2016, faces a potential two-year delay due to regulatory concerns flagged by SEBI, despite recent improvements in share transfer efficiency.
India's defence manufacturing achieved Rs. 1.27 lakh crore output in FY24 and aims for Rs. 3 lakh crore by 2029 through indigenous development and policy reforms.


#129 India Insight: GOI’s 23k Cr PLI for EMS, NSE 2 Yrs IPO Delay?, Indian Defence Soars

Equity Derivatives

Bombay Stock Exchange / Equity Derivatives

<ul>
<li>SEBI's March 27 proposal suggests standardising expiry dates: Thursdays for <a href="https://www.smartkarma.com/entities/bombay-stock-exchange" target="_blank" data-smartkarma-citation="entities:23694:1" rel="noopener">Bombay Stock Exchange (BSE IN)</a> and Tuesdays for <a href="https://www.smartkarma.com/entities/national-stock-exchange" target="_blank" data-smartkarma-citation="entities:23751:1" rel="noopener">National Stock Exchange (NSEIN IN)</a> .</li>
<li>NSE's previous strategic expiry days aimed at better liquidity, marginalising BSE's Tuesday expiry, potentially impacting it's trading volumes.</li>
<li>Post-Consultation was released, NSE faces a setback, deferring its planned monday expiry shift for Nifty contracts, indirectly protecting BSE from market share erosion.</li>
</ul>


SEBI's March 27 proposal suggests standardising expiry dates: Thursdays for Bombay Stock Exchange (BSE IN) and Tuesdays for National Stock Exchange (NSEIN IN) .
NSE's previous strategic expiry days aimed at better liquidity, marginalising BSE's Tuesday expiry, potentially impacting it's trading volumes.
Post-Consultation was released, NSE faces a setback, deferring its planned monday expiry shift for Nifty contracts, indirectly protecting BSE from market share erosion.


How SEBI's Expiry Date Proposal Could Halt BSE’s Market Share Erosion?

India

National Stock Exchange of India Ltd. operates as a stock exchange that provides automated screen-based trading system. The Company offers a range of products and services for various markets, including equities, indices, mutual and exchange traded funds, initial public offerings, security lending scheme, and institutional placement programs. ... More

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

National Stock Exchange (NSEIN IN)

Pine Labs Pre-IPO - The Positives - Some Segments Growing..

Pine Labs is looking to raise up to US$1bn in its upcoming India IPO. In this note, we talk about the positive aspects of the deal.

Sumeet Singh

Anthem Biosciences IPO - D&M Vertical Continues to Drive CRDMO Business

Anthem Biosciences is looking to raise about US$397m in its India IPO. In this note, we will talk about the RHP updates.

Akshat Shah

Swiggy (SWIGGY IN): US$7.6bn Lock-Up Expiry & Index Inclusion

There is a US$7.6bn lock-up expiry in Swiggy on 12 May - 80% of that is PE/VC, so expect selling. The stock could remain under pressure but PE/VC...

Brian Freitas

#129 India Insight: GOI’s 23k Cr PLI for EMS, NSE 2 Yrs IPO Delay?, Indian Defence Soars

Cabinet approves PLI for non-semiconductor electronics, NSEIN's IPO faces delay, India aims for Rs. 3 lakh crore defence manufacturing output by...

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pine Labs Pre-IPO - The Positives - Some Segments Growing..

Pine Labs is looking to raise up to US$1bn in its upcoming India IPO. In this note, we talk about the positive aspects of the deal.

Sumeet Singh

Anthem Biosciences IPO - D&M Vertical Continues to Drive CRDMO Business

Anthem Biosciences is looking to raise about US$397m in its India IPO. In this note, we will talk about the RHP updates.

Akshat Shah

Swiggy (SWIGGY IN): US$7.6bn Lock-Up Expiry & Index Inclusion

There is a US$7.6bn lock-up expiry in Swiggy on 12 May - 80% of that is PE/VC, so expect selling. The stock could remain under pressure but PE/VC...

Brian Freitas

#129 India Insight: GOI’s 23k Cr PLI for EMS, NSE 2 Yrs IPO Delay?, Indian Defence Soars

​Cabinet approves PLI for non-semiconductor electronics, NSEIN's IPO faces delay, India aims for Rs. 3 lakh crore defence manufacturing output by...

Sudarshan Bhandari

How SEBI's Expiry Date Proposal Could Halt BSE’s Market Share Erosion?

​SEBI proposes standardising expiry dates for BSE and NSE, impacting liquidity and trading volumes, with NSE facing setback in shifting to Monday...

Sudarshan Bhandari

Cabinet approves PLI for non-semiconductor electronics, NSEIN's IPO faces delay, India aims for Rs. 3 lakh crore defence manufacturing output by...

SEBI proposes standardising expiry dates for BSE and NSE, impacting liquidity and trading volumes, with NSE facing setback in shifting to Monday...